The North America Anti-Obesity Drugs Market would witness market growth of 9.3% CAGR during the forecast period (2023-2029).
The peripherally acting anti-obesity medications and the centrally acting anti-obesity drugs are the two primary subcategories that fall under the umbrella of the anti-obesity drug category. Anti-obesity drugs that work on the body's peripheral systems aid in weight loss without affecting the brain or hunger. The product inhibits the action of pancreatic lipase, which in turn impedes the hydrolysis of lipids in the gastrointestinal system and reduces the absorption of fat in the intestinal tract. There are many different kinds of medications, such as those that require a doctor's prescription and those that can be purchased without a doctor's permission.
These treatments could either be considered monotherapies or polytherapy, depending on how they are combined. On a national, regional, and international scale, obesity is a serious threat to public health. Because of an increase in the consumption of processed and unhealthy foods, a decrease in the amount of time spent being physically active, and a lack of understanding regarding the associated health hazards, the prevalence rate of obesity is increasing all over the region. As a consequence of this, the anticipated rise in demand for anti-obesity medication is anticipated to drive the expansion of the market.
According to Statistics Canada, the majority of adults in Canada are overweight or obese, with two out of every three falling into this category. In addition, the prevalence of childhood obesity has increased significantly over the past 25 years. The rise was observed in both male and female demographics and across all age brackets, except for those in the preschool category. Moreover, over 50% of Canadian children and adolescents do not engage in sufficient physical activity to achieve their maximum potential for growth and development. Thus, the growing prevalence of obesity among the regional population is expected to increase the demand and utilization of anti-obesity drugs propelling the market growth in the region.
The US market dominated the North America Anti-Obesity Drugs Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $781.6 million by 2029. The Canada market is poised to grow at a CAGR of 11.5% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 11.2% during (2023 - 2029).
Based on Drug Type, the market is segmented into Prescription Drugs and Over The Counter Drugs. Based on Mechanism of Action, the market is segmented into Centrally Acting and Peripherally Acting. Based on Route Of Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Anti-Obesity Drugs Market is Projected to reach USD 3.1 Billion by 2029, at a CAGR of 10.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Vivus LLC, CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH) and KVK Tech, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Prescription Drugs
- Over The Counter Drugs
By Mechanism of Action
- Centrally Acting
- Peripherally Acting
By Route Of Administration
- Oral Route
- Subcutaneous Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- Gelesis Holdings Inc. (PureTech Health)
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Vivus LLC
- CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
- KVK Tech, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Anti-Obesity Drugs Market, by Drug Type
1.4.2 North America Anti-Obesity Drugs Market, by Mechanism of Action
1.4.3 North America Anti-Obesity Drugs Market, by Route Of Administration
1.4.4 North America Anti-Obesity Drugs Market, by Distribution Channel
1.4.5 North America Anti-Obesity Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Anti-Obesity Drugs Market by Drug Type
3.1 North America Prescription Drugs Market by Country
3.2 North America Over The Counter Drugs Market by Country
Chapter 4. North America Anti-Obesity Drugs Market by Mechanism of Action
4.1 North America Centrally Acting Market by Country
4.2 North America Peripherally Acting Market by Country
Chapter 5. North America Anti-Obesity Drugs Market by Route Of Administration
5.1 North America Oral Route Market by Country
5.2 North America Subcutaneous Route Market by Country
Chapter 6. North America Anti-Obesity Drugs Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Retail Pharmacies Market by Country
6.3 North America Online Pharmacies Market by Country
Chapter 7. North America Anti-Obesity Drugs Market by Country
7.1 US Anti-Obesity Drugs Market
7.1.1 US Anti-Obesity Drugs Market by Drug Type
7.1.2 US Anti-Obesity Drugs Market by Mechanism of Action
7.1.3 US Anti-Obesity Drugs Market by Route Of Administration
7.1.4 US Anti-Obesity Drugs Market by Distribution Channel
7.2 Canada Anti-Obesity Drugs Market
7.2.1 Canada Anti-Obesity Drugs Market by Drug Type
7.2.2 Canada Anti-Obesity Drugs Market by Mechanism of Action
7.2.3 Canada Anti-Obesity Drugs Market by Route Of Administration
7.2.4 Canada Anti-Obesity Drugs Market by Distribution Channel
7.3 Mexico Anti-Obesity Drugs Market
7.3.1 Mexico Anti-Obesity Drugs Market by Drug Type
7.3.2 Mexico Anti-Obesity Drugs Market by Mechanism of Action
7.3.3 Mexico Anti-Obesity Drugs Market by Route Of Administration
7.3.4 Mexico Anti-Obesity Drugs Market by Distribution Channel
7.4 Rest of North America Anti-Obesity Drugs Market
7.4.1 Rest of North America Anti-Obesity Drugs Market by Drug Type
7.4.2 Rest of North America Anti-Obesity Drugs Market by Mechanism of Action
7.4.3 Rest of North America Anti-Obesity Drugs Market by Route Of Administration
7.4.4 Rest of North America Anti-Obesity Drugs Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.2 Boehringer Ingelheim International Gmbh
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 GlaxoSmithKline PLC (GSK)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 Novo Nordisk A/S
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental & Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 Rhythm Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.6 Gelesis Holdings Inc (PureTech Health)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.6.4.2 Approvals and Trials:
8.7 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Acquisition and Mergers:
8.8 Vivus LLC
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Approvals and Trials:
8.9 CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
8.9.1 Company Overview
8.10. KVK Tech, Inc.
8.10.1 Company Overview
TABLE 1 North America Anti-Obesity Drugs Market, 2019 - 2022, USD Million
TABLE 2 North America Anti-Obesity Drugs Market, 2023 - 2029, USD Million
TABLE 3 North America Anti-Obesity Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 4 North America Anti-Obesity Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 5 North America Prescription Drugs Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Prescription Drugs Market by Country, 2023 - 2029, USD Million
TABLE 7 North America Over The Counter Drugs Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Over The Counter Drugs Market by Country, 2023 - 2029, USD Million
TABLE 9 North America Anti-Obesity Drugs Market by Mechanism of Action, 2019 - 2022, USD Million
TABLE 10 North America Anti-Obesity Drugs Market by Mechanism of Action, 2023 - 2029, USD Million
TABLE 11 North America Centrally Acting Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Centrally Acting Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Peripherally Acting Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Peripherally Acting Market by Country, 2023 - 2029, USD Million
TABLE 15 North America Anti-Obesity Drugs Market by Route Of Administration, 2019 - 2022, USD Million
TABLE 16 North America Anti-Obesity Drugs Market by Route Of Administration, 2023 - 2029, USD Million
TABLE 17 North America Oral Route Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Oral Route Market by Country, 2023 - 2029, USD Million
TABLE 19 North America Subcutaneous Route Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Subcutaneous Route Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Anti-Obesity Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 22 North America Anti-Obesity Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 23 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 25 North America Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Online Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Online Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Anti-Obesity Drugs Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Anti-Obesity Drugs Market by Country, 2023 - 2029, USD Million
TABLE 31 US Anti-Obesity Drugs Market, 2019 - 2022, USD Million
TABLE 32 US Anti-Obesity Drugs Market, 2023 - 2029, USD Million
TABLE 33 US Anti-Obesity Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 34 US Anti-Obesity Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 35 US Anti-Obesity Drugs Market by Mechanism of Action, 2019 - 2022, USD Million
TABLE 36 US Anti-Obesity Drugs Market by Mechanism of Action, 2023 - 2029, USD Million
TABLE 37 US Anti-Obesity Drugs Market by Route Of Administration, 2019 - 2022, USD Million
TABLE 38 US Anti-Obesity Drugs Market by Route Of Administration, 2023 - 2029, USD Million
TABLE 39 US Anti-Obesity Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 40 US Anti-Obesity Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 41 Canada Anti-Obesity Drugs Market, 2019 - 2022, USD Million
TABLE 42 Canada Anti-Obesity Drugs Market, 2023 - 2029, USD Million
TABLE 43 Canada Anti-Obesity Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 44 Canada Anti-Obesity Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 45 Canada Anti-Obesity Drugs Market by Mechanism of Action, 2019 - 2022, USD Million
TABLE 46 Canada Anti-Obesity Drugs Market by Mechanism of Action, 2023 - 2029, USD Million
TABLE 47 Canada Anti-Obesity Drugs Market by Route Of Administration, 2019 - 2022, USD Million
TABLE 48 Canada Anti-Obesity Drugs Market by Route Of Administration, 2023 - 2029, USD Million
TABLE 49 Canada Anti-Obesity Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Canada Anti-Obesity Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 51 Mexico Anti-Obesity Drugs Market, 2019 - 2022, USD Million
TABLE 52 Mexico Anti-Obesity Drugs Market, 2023 - 2029, USD Million
TABLE 53 Mexico Anti-Obesity Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 54 Mexico Anti-Obesity Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 55 Mexico Anti-Obesity Drugs Market by Mechanism of Action, 2019 - 2022, USD Million
TABLE 56 Mexico Anti-Obesity Drugs Market by Mechanism of Action, 2023 - 2029, USD Million
TABLE 57 Mexico Anti-Obesity Drugs Market by Route Of Administration, 2019 - 2022, USD Million
TABLE 58 Mexico Anti-Obesity Drugs Market by Route Of Administration, 2023 - 2029, USD Million
TABLE 59 Mexico Anti-Obesity Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Mexico Anti-Obesity Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 61 Rest of North America Anti-Obesity Drugs Market, 2019 - 2022, USD Million
TABLE 62 Rest of North America Anti-Obesity Drugs Market, 2023 - 2029, USD Million
TABLE 63 Rest of North America Anti-Obesity Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 Rest of North America Anti-Obesity Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 Rest of North America Anti-Obesity Drugs Market by Mechanism of Action, 2019 - 2022, USD Million
TABLE 66 Rest of North America Anti-Obesity Drugs Market by Mechanism of Action, 2023 - 2029, USD Million
TABLE 67 Rest of North America Anti-Obesity Drugs Market by Route Of Administration, 2019 - 2022, USD Million
TABLE 68 Rest of North America Anti-Obesity Drugs Market by Route Of Administration, 2023 - 2029, USD Million
TABLE 69 Rest of North America Anti-Obesity Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 70 Rest of North America Anti-Obesity Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 71 Key Information – Pfizer, Inc.
TABLE 72 Key Information – Boehringer Ingelheim International GmbH
TABLE 73 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 74 Key information – Novo Nordisk A/S
TABLE 75 Key Information – Rhythm Pharmaceuticals, Inc
TABLE 76 Key Information – Gelesis Holdings Inc.
TABLE 77 Key Information – Currax Pharmaceuticals LLC
TABLE 78 Key Information – Vivus LLC
TABLE 79 Key Information – CHEPLAPHARM Arzneimittel GmbH
TABLE 80 Key Information – KVK Tech, Inc.
List of Figures
FIG 1 Methodology for the research